New investment fund raises $310 million for biotech incubation

8 February 2024
money_big-1

New York-based healthcare investor Scion Life Sciences has closed its inaugural fund, with commitments of $310 million having been made.

The money will be used to found and build biotechnology companies that discover, develop and seek to commercialize new therapies in areas of high unmet medical need.

An affiliate of Petrichor, Scion was founded and is led by investors Samuel Hall and Aaron Kantoff, together with Petrichor managing partner Tadd Wessel.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Biotechnology